SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ProMetic Life Sciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: axial3/6/2017 4:37:46 AM
   of 250
 
Excerpt : 2017 RBC Capital Markets’ Healthcare Conference

Unconfirmed — no link available. Original post here.

Edited for clarity. Content unchanged.
______________________________________________

'ProMetic Life Sciences Inc. (TSX: PLI
2017 RBC Capital Markets’ Healthcare Conference: Updates from Day 1

February 23, 2017 11

Pierre Laurin, President and CEO, presented.

Plasminogen:
  • Management anticipates the rolling BLA (initiated Dec/16) should be complete over the next couple of weeks and anticipates a launch in Q3/17. The plasminogen congenital deficiency market is ~6K patients worldwide and is often misdiagnosed. ProMetic continues to build its plasminogen patient registry and noted that it believes treatment will consist of a mix of on-demand treatment and maintenance therapy.
  • In terms of insurance coverage for plasminogen, ProMetic has been working with payors over the past 1.5 years and the roll-out of its medical science liaison (MSL) team in the US has allowed the company to educate both hematologists and ophthalmologists on the presenting signs of plasminogen deficiency.
  • ProMetic also noted that it has been able to limit the size of its MSL team as just 250 hospitals and specialists in the US treat ~90% of plasminogen deficient patients, allowing the team to concentrate its efforts.

PBI-4050: The conversation on PBI-4050 focused on this morning’s Ph. II IPF data and future plans for PBI-4050.
  • Management intends to initiate a placebo-controlled pivotal Ph. II/III trial in Q2/17 studying PBI-4050 as a monotherapy and combination therapy in patients with IPF. This trial will likely enroll ~100 patients and will cost ~$10–15MM. After six months on therapy, the trial could potentially pivot to a Ph. III.
  • Although we do not know which current IPF treatment (pirfenidone or nintedanib) outperformed when used as a combination therapy, PLI intends to disclose the drug which outperformed as a combination therapy in Q2/17 ahead of its abstract presentation at the American Thoracic Society meeting in May. The company is currently investigating why one therapy outperformed.
  • In terms of licensing, management leaned heavily toward potential regional partnerships for PBI-4050 (we anticipate Japan and China) and noted it would prefer to advance analogues of PBI-4050 and then license those drugs for more specific indications.'
Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News